Apr 04, 2012 9:30am EDT Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
Jan 09, 2012 9:00am EST Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases
Dec 19, 2011 9:00am EST Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
Sep 22, 2011 9:00am EDT Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Lead Anti-Cancer Compound
Mar 02, 2011 10:39am EST Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
Oct 05, 2010 9:00am EDT Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
Jul 02, 2009 9:00am EDT Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
Aug 19, 2008 8:15am EDT Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
